OR WAIT null SECS
The Biden administration’s choice to lead FDA successfully navigated a Senate confirmation hearing on Dec. 14, setting the stage for full Senate approval early next year. The leading Republican on the Senate Health, Education, Labor and Pensions (HELP) committee, Sen. Richard Burr, praised the stellar academic and medical research credentials of his fellow North Carolinian, eliciting support from other Republicans on the panel. HELP Committee chair Patty Murray (D-Wash.) set the stage for a speedy conclusion to the vetting process and votes on Califf’s confirmation in early January.
The main opposition to Califf came from liberal Democrat Sen. Bernie Sanders (I-Vt), who questioned the nominee’s long ties to the drug industry and involvement in industry research that has generated high-priced medicines. At the same time, Califf received letters of support from six former FDA commissioners and a long list of academic, public health and patient organizations. The nominee, who headed FDA in 2016, said he would hit the ground running and noted the importance of working closely with Congress and other federal health agencies.
The main point of controversy during the two-hour hearing centered on FDA approval of opioids leading to the addiction and hundreds of thousands of deaths from drug overdoses. Califf promised irate Senators from New Mexico and New Hampshire that he would take a “very aggressive approach” towards opioids and conduct a “comprehensive review” of their status and labeling as a first order of business.